Nick Pizzie, Chief Financial Officer at Axsome Therapeutics, Inc. (AXSM), sold 33,000 shares at $240.09 ($7.9M) on 2026-06-09, disclosed to the SEC on 2026-06-09.
Scheduled sale ($7.9M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AXSM | BUY | 2021-11-22 | $34K | — | Filing → |
| AXSM | BUY | 2020-06-30 | $119K | — | Filing → |
| AXSM | BUY | 2019-09-30 | $54K | — | Filing → |